CL2011002597A1 - Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis. - Google Patents
Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis.Info
- Publication number
- CL2011002597A1 CL2011002597A1 CL2011002597A CL2011002597A CL2011002597A1 CL 2011002597 A1 CL2011002597 A1 CL 2011002597A1 CL 2011002597 A CL2011002597 A CL 2011002597A CL 2011002597 A CL2011002597 A CL 2011002597A CL 2011002597 A1 CL2011002597 A1 CL 2011002597A1
- Authority
- CL
- Chile
- Prior art keywords
- traveler
- enteritis
- crohn
- diarrhea
- treat
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000011231 Crohn disease Diseases 0.000 title abstract 2
- 206010012735 Diarrhoea Diseases 0.000 title abstract 2
- 208000004232 Enteritis Diseases 0.000 title abstract 2
- 229930189077 Rifamycin Natural products 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960003292 rifamycin Drugs 0.000 title abstract 2
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title abstract 2
- 208000012868 Overgrowth Diseases 0.000 title 1
- 208000007386 hepatic encephalopathy Diseases 0.000 title 1
- 208000028774 intestinal disease Diseases 0.000 title 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000032274 Encephalopathy Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
Abstract
SE REVELAN COMPUESTOS DERIVADOS DE RIFAMICINA DE FÓRMULA I, ET PROCEDIMIENTO DE PREPARACIÓN <em>DE </em>ESTOS COMPUESTOS UTILIZANDO UN COMPUESTO DE FÓRMULA II Y III; LA COMPOSICIÓN FARMACÉUTICA QUE LOS CONTIENE; Y SU USO PARA TRATAR, PREVENIR O ALIVIAR EL SOBRECRECIMIENTO BACTERIANO EN TRASTORNOS INTESTINALES TALES COMO SINDROME DE COLON IRRITABLE, DIARREA DEL VIAJANTE, ENFERMEDAD DE CROHN, ENCEFALOPATIA HEPÁTICA Y ENTERITIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A000653A IT1397617B1 (it) | 2009-04-20 | 2009-04-20 | Nuovi derivati della rifamicina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011002597A1 true CL2011002597A1 (es) | 2012-03-23 |
Family
ID=41228810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011002597A CL2011002597A1 (es) | 2009-04-20 | 2011-10-18 | Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis. |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8318763B2 (es) |
| EP (1) | EP2421869B1 (es) |
| JP (1) | JP5661100B2 (es) |
| KR (1) | KR101555860B1 (es) |
| CN (1) | CN102405223A (es) |
| AR (1) | AR076340A1 (es) |
| AU (1) | AU2010240638B2 (es) |
| BR (1) | BRPI1005979A8 (es) |
| CA (1) | CA2743801C (es) |
| CL (1) | CL2011002597A1 (es) |
| CO (1) | CO6362013A2 (es) |
| DK (1) | DK2421869T3 (es) |
| EA (1) | EA020201B1 (es) |
| ES (1) | ES2535327T3 (es) |
| HR (1) | HRP20110437A2 (es) |
| IL (1) | IL212942A (es) |
| IT (1) | IT1397617B1 (es) |
| MA (1) | MA33320B1 (es) |
| MX (1) | MX338334B (es) |
| NZ (1) | NZ595884A (es) |
| PL (1) | PL2421869T3 (es) |
| PT (1) | PT2421869E (es) |
| SG (1) | SG171989A1 (es) |
| TN (1) | TN2011000265A1 (es) |
| TW (1) | TWI422372B (es) |
| UA (1) | UA105775C2 (es) |
| WO (1) | WO2010122436A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1698630T3 (da) | 2005-03-03 | 2014-12-08 | Alfa Wassermann Spa | Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
| ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
| ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
| EA201590447A1 (ru) * | 2012-09-12 | 2015-06-30 | Сэликс Фармасьютиклз, Лтд. | Способы введения рифаксимина без развития устойчивости к антибиотикам |
| CN103709177B (zh) * | 2013-12-20 | 2016-02-24 | 武汉工程大学 | 利福霉素类沃尼妙林杂合抗生素及其制备方法 |
| PL3143027T3 (pl) * | 2014-05-12 | 2019-11-29 | Alfasigma Spa | Nowe solwatowane krystaliczne postaci rifaksyminy, ich wytwarzanie, kompozycje i zastosowania |
| RU2020102511A (ru) | 2017-06-26 | 2021-07-27 | Биофер С.П.А. | Соединения пиридо-имидазо рифамицина в качестве антибактериального средства |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH547854A (de) * | 1969-05-30 | 1974-04-11 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von antibiotika. |
| SU465795A3 (ru) * | 1972-05-05 | 1975-03-30 | Группо Лепетит (Фирма) | Способ получени рифамицина в. |
| CH571064A5 (en) * | 1973-03-01 | 1975-12-31 | Archifar Ind Chim Trentino | Recovery of rieamycin from broths - by oxidn to an insol form |
| US3847903A (en) * | 1973-03-01 | 1974-11-12 | Archifar Ind Chim Trentino | Method for extracting and isolating rifamycin o from fermentation broths of rifamycins |
| US4267274A (en) * | 1973-04-26 | 1981-05-12 | Gruppo Lepetit S.P.A. | Streptomyces mediterranei mutant capable of production of rifamycin B |
| GB1470426A (en) * | 1974-08-30 | 1977-04-14 | Lepetit Spa | Rifamycins |
| IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
| IT1199374B (it) * | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
| US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
| ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
-
2009
- 2009-04-20 IT ITMI2009A000653A patent/IT1397617B1/it active
- 2009-05-27 US US12/473,260 patent/US8318763B2/en active Active
-
2010
- 2010-03-18 HR HR20110437A patent/HRP20110437A2/hr not_active Application Discontinuation
- 2010-03-18 SG SG2011041225A patent/SG171989A1/en unknown
- 2010-03-18 CA CA2743801A patent/CA2743801C/en active Active
- 2010-03-18 PL PL10714069T patent/PL2421869T3/pl unknown
- 2010-03-18 PT PT107140691T patent/PT2421869E/pt unknown
- 2010-03-18 EA EA201190216A patent/EA020201B1/ru not_active IP Right Cessation
- 2010-03-18 AU AU2010240638A patent/AU2010240638B2/en not_active Ceased
- 2010-03-18 ES ES10714069.1T patent/ES2535327T3/es active Active
- 2010-03-18 BR BRPI1005979A patent/BRPI1005979A8/pt not_active Application Discontinuation
- 2010-03-18 CN CN2010800174395A patent/CN102405223A/zh active Pending
- 2010-03-18 JP JP2012505257A patent/JP5661100B2/ja active Active
- 2010-03-18 EP EP10714069.1A patent/EP2421869B1/en active Active
- 2010-03-18 DK DK10714069.1T patent/DK2421869T3/da active
- 2010-03-18 WO PCT/IB2010/051183 patent/WO2010122436A1/en not_active Ceased
- 2010-03-18 MA MA33963A patent/MA33320B1/fr unknown
- 2010-03-18 KR KR1020117013848A patent/KR101555860B1/ko active Active
- 2010-03-18 NZ NZ595884A patent/NZ595884A/xx not_active IP Right Cessation
- 2010-03-18 MX MX2011011026A patent/MX338334B/es active IP Right Grant
- 2010-03-18 UA UAA201106234A patent/UA105775C2/uk unknown
- 2010-04-12 TW TW099111234A patent/TWI422372B/zh not_active IP Right Cessation
- 2010-04-20 AR ARP100101301A patent/AR076340A1/es unknown
-
2011
- 2011-05-17 IL IL212942A patent/IL212942A/en active IP Right Grant
- 2011-05-24 TN TN2011000265A patent/TN2011000265A1/fr unknown
- 2011-06-22 CO CO11078443A patent/CO6362013A2/es not_active Application Discontinuation
- 2011-10-18 CL CL2011002597A patent/CL2011002597A1/es unknown
-
2012
- 2012-11-26 US US13/684,803 patent/US8765778B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002597A1 (es) | Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis. | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2012003226A1 (es) | Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas. | |
| UY33238A (es) | "Compuestos en calidad de antagonistas de bradiquinina-b1" | |
| GT201000376A (es) | Compuestos organicos | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| CL2007000742A1 (es) | Compuestos derivados de 2-oxoimidazol, moduladores del recptor s1p (esfingosina-1-fosfato); composicion farmceutica que los contiene; y su uso para tratar condiciones tales como rechazo de trasplante, cancer, artritis reumatoide y diabetes. | |
| CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2012000302A1 (es) | Compuestos derivados de tubulisinas; compuestos conjugados que los comprenden; compuestos intermediarios; y uso para tratar el cancer. | |
| CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CL2008003188A1 (es) | Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met. | |
| ECSP066856A (es) | Compuestos novedosos como moduladores del receptor opioide | |
| CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| NI201000110A (es) | Derivados bicíclicos para usar en el tratamiento de afecciones asociadas con el receptor de andrógeno. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| ECSP099751A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo[4,5-b]piridin-5-amina y su uso para el tratamiento del cáncer | |
| MX2009009153A (es) | Pirano-pirazol-aminas. | |
| CO6290655A2 (es) | Inhibidors heterociclicos de estearoil-coa-desaturasa | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 |